Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 56 points (-0.3%) at 15,939 as of Wednesday, Feb. 12, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,598 issues advancing vs. 1,323 declining with 154 unchanged. The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Seattle Genetics ( SGEN), up 11.4%, Incyte ( INCY), up 4.3%, Jazz Pharmaceuticals ( JAZZ), up 4.5%, Biomarin Pharmaceutical ( BMRN), up 3.4% and GlaxoSmithKline ( GSK), up 1.1%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 1.4%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.70 (1.1%) to $66.16 on light volume. Thus far, 590,003 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $65.92-$66.42 after having opened the day at $65.92 as compared to the previous trading day's close of $65.46. AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $81.0 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate AstraZeneca a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.